International Clinical Trial: Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07432984) titled 'Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC' on Feb. 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Se-Hoon Lee

Condition: Non Small Cell Lung Cancer

Intervention: Drug: Tislelizumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 30, 2026

Target Sample Size: 15

To know more, visit https://clinicaltrials.gov/study/NCT07432984

Published by HT Digital Content Services with permission from ...